JP2023526517A5 - - Google Patents

Info

Publication number
JP2023526517A5
JP2023526517A5 JP2022571228A JP2022571228A JP2023526517A5 JP 2023526517 A5 JP2023526517 A5 JP 2023526517A5 JP 2022571228 A JP2022571228 A JP 2022571228A JP 2022571228 A JP2022571228 A JP 2022571228A JP 2023526517 A5 JP2023526517 A5 JP 2023526517A5
Authority
JP
Japan
Prior art keywords
leucine
acetyl
acetazolamide
aminopyridine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022571228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526517A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/054399 external-priority patent/WO2021234642A1/en
Publication of JP2023526517A publication Critical patent/JP2023526517A/ja
Publication of JP2023526517A5 publication Critical patent/JP2023526517A5/ja
Pending legal-status Critical Current

Links

JP2022571228A 2020-05-22 2021-05-20 運動失調症を治療するためのアセチルロイシンと4-アミノピリジン又はアセタゾラミドとの組合せ Pending JP2023526517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063028760P 2020-05-22 2020-05-22
US63/028,760 2020-05-22
PCT/IB2021/054399 WO2021234642A1 (en) 2020-05-22 2021-05-20 The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia

Publications (2)

Publication Number Publication Date
JP2023526517A JP2023526517A (ja) 2023-06-21
JP2023526517A5 true JP2023526517A5 (https=) 2024-05-29

Family

ID=76181172

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022571228A Pending JP2023526517A (ja) 2020-05-22 2021-05-20 運動失調症を治療するためのアセチルロイシンと4-アミノピリジン又はアセタゾラミドとの組合せ

Country Status (7)

Country Link
US (1) US20230201150A1 (https=)
EP (1) EP4153161A1 (https=)
JP (1) JP2023526517A (https=)
KR (1) KR20230015433A (https=)
CA (1) CA3179105A1 (https=)
MX (1) MX2022014466A (https=)
WO (1) WO2021234642A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
WO2025264957A2 (en) * 2024-06-20 2025-12-26 Intrabio Inc. Acetyl leucine for treating neurodevelopmental disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
JP2009269856A (ja) * 2008-05-07 2009-11-19 Nobufumi Ono 異常行動防止薬及びこれを含むインフルエンザ治療薬
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
CA2825810A1 (en) * 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of 4-aminopyridine to treat cerebral palsy
TN2016000259A1 (en) * 2016-06-27 2017-10-06 Rekik Raouf Salbutamol (albuterol) eye protective medicament.
WO2018029658A1 (en) * 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
WO2021048431A1 (en) * 2019-09-12 2021-03-18 Amabiotics Compounds for treating ataxia

Similar Documents

Publication Publication Date Title
JP2023526517A5 (https=)
WO2005009349A2 (en) Composition and method for treating neurological disorders
JP2017513908A5 (https=)
EP1959988B1 (en) Use of bovine lactoferrin for treating destructive inflammation of mucous membrane
JP2020521797A5 (https=)
JP2023522010A5 (https=)
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
US5756478A (en) Method for reducing toxicity of D-nucleoside analogs with L-nucleosides
JP2024516795A5 (https=)
JP2005504782A5 (https=)
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
JP2013504603A5 (https=)
JP2021512921A5 (https=)
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина
JP2025525989A5 (https=)
EA028495B1 (ru) Пероральная композиция для лечения подагры на основе (-)-галофената и колхицина
EP1847274A1 (en) Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy
JP2023538125A (ja) 粘液過剰分泌を特徴とする呼吸器疾患を処置するための方法
CN116919955B (zh) 一种小分子化合物gi-y2在制备药物及抑制剂中的应用
EP3592351A1 (en) 1-piperidinepropionic acid for treating a fibrosing disease
US20020071814A1 (en) Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation
JP2025532676A5 (https=)
WO2023193705A1 (zh) 西奥罗尼在抗胰腺癌中的用途
JP2025522146A5 (https=)